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PURPOSE: To present experience with high dose-rate endobronchial brachytherapy in the treatment of primary tracheal
tumors.
PATIENTS AND METHODS: Four patients with nonresected primary tracheal tumors are presented: 2 cases of squamous
cell carcinoma of the trachea, 1 of recurrent adenoid cystic carcinoma, and 1 with recurrent plasmacytoma. All received
brachytherapy, alone or as a boost for primary irradiation, in 3 or 4 fractions of 7.5 Gy, calculated at a depth of 1 cm. Follow-
up was considered to start from the end of brachytherapy.
RESULTS: Local control was achieved in all cases at the time of first bronchoscopic evaluation. Two patients with squamous
cell carcinoma died at 6th and 33rd months after brachytherapy, respectively. The first had no evidence of disease, and the
latter had local recurrence. The other 2 patients were alive after 64 and 110 months of follow-up, respectively, both with no
evidence of disease. Tracheal stenosis developed in these 2 cases, 22 and 69 months after brachytherapy. Tracheal stent
placement was needed only for the patient with an adenoid cystic carcinoma.
CONCLUSIONS: Endobronchial high dose-rate brachytherapy may be used for tracheal tumors, even as a boost for external
beam irradiation, or in recurrences. Local control in 3 out of 4 patients indicates that individual cases may benefit from the
treatment. Long-term survival may also be expected, mainly for tumors with adenoid cystic histology.
KEYWORDS: Radiotherapy. Brachytherapy. Tracheal tumors. High dose-rate. Complications.
Brachytherapy is the radiation treatment in which the
radioactive material is located in contact with or inside the
target lesion. Special applicators, needles, and catheters are
used as guides for positioning the radioactive material in
the patient. Endobronchial brachytherapy is performed
through bronchoscopy, with the placement of one or more
catheters in the lower airways. Brachytherapy has been
widely used, especially after the development of high dose-
rate (HDR) remote afterloading machines. In 1991, our group
first introduced this method in Latin America.1 The advan-
tages obtained with the use of HDR brachytherapy include
good patient tolerance, short treatment time, and a higher
potential to achieve local control.
The highly conformal nature of brachytherapy enables
the radiation oncologist to accomplish safe escalation of
radiation doses to the tumor while minimizing doses to nor-
mal surrounding structures. Most of the reported experience
with endobronchial brachytherapy is related to treatment
of primary or metastatic endobronchial lesions, either with
curative or palliative intent. Very few articles report the use
of brachytherapy for primary tracheal tumors.2-7 Due to the
rarity of the disease (0.2% - 0.5% of all upper respiratory
tract malignancies),8,9 the role of endoluminal brachytherapy
in the treatment regimen of tracheal neoplasms has not been
clearly defined yet.
Prognostic factors include performance status, weight
loss, histological type, location in the trachea (upper, mid-
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dle, or lower third), resectability, lymph node involvement,
and surgical margins.10,11
Adenoid cystic carcinoma and squamous cell carcinoma
are the most common tracheal tumors. Resection and post-
operative radiation therapy are the treatment of choice.12,13
Complete resection is the desired goal, and benign tumors,
for which cure can be expected, are best treated by resec-
tion alone.
We report the experience of a single institution with
high dose-rate brachytherapy in the management of
nonresected primary tracheal tumors.
MATERIALS AND METHODS
From 1991 to 1997, four patients with primary tracheal
tumors were treated with endobronchial/endotracheal HDR
brachytherapy: two men with squamous cell carcinoma,
and two women, one with adenoid cystic carcinoma, one
with primary tracheal plasmacytoma (previously published
as a case report).14 Brachytherapy was indicated as a boost
after external beam irradiation in 1 case of inoperable sq-
uamous carcinoma of the lower third of the trachea, which
was asymptomatic at that time. The other patient with sq-
uamous cell carcinoma was previously irradiated for a
head and neck tumor and received brachytherapy alone.
He had an inoperable tumor located at the upper portion
of the trachea, causing dyspnea, cough, and mild bleed-
ing right below the supraclavicular radiation field limits.
The 2 patients with adenoid cystic carcinoma and plas-
macytoma, respectively, underwent brachytherapy as a sal-
vage treatment for local recurrences after external beam
irradiation years before (9 and 11 years, respectively). Di-
agnosis of recurrence was made after complaints of dyspnea
and cough with mild bleeding in the first case and cough
in the second one. Only the patient with plasmacytoma
received laser therapy for debulking before irradiation.14
Table 1 presents patient characteristics, and Table 2
presents previous radiation treatments.
Endotracheal HDR brachytherapy was delivered in 3 or
4 fractions of 7.5 Gy each, at weekly intervals. Dose calcu-
lation was made at 1 cm from the source axis, with optimi-
zation on dose points. No centered catheters were available,
and 6Fr catheters were used in all procedures. Nasal place-
ment and fixation of the catheters with tape was used, ex-
cept for the patient with previous larynx carcinoma, where
the procedure was performed through the tracheotomy. One
or two catheters were placed in the tracheal lumen and po-
sitioned in the right and/or left main bronchus, respectively.
Proximal and distal margins of 1 to 2 cm from the lesion
were included in the treatment volume, to account for pos-
sible variations due to respiratory cycles. Since there may
be areas of very high radiation doses where the catheter sur-
face is in contact with the airway mucosa, the volumes re-
ceiving the total dose (100%), and those receiving 150%
and 200% of the total dose were also evaluated (Table 3).
Follow-up was considered to start from the end of
brachytherapy. The local response was evaluated by
fiberbronchoscopy performed 30 to 40 days after the end
of brachytherapy. Subsequent bronchoscopies were per-
formed at 3 and 6 months after brachytherapy, and after that
whenever indicated. Additionally, thoracic CT scans were
performed every 6 months over the first 3 years, then yearly
until at least 5 years of follow-up.
Table 1 - Description of patient characteristics
Patient Gender Age Histology DFS Tracheal Ext. Obstr. LN
(years) location Score*
1 M 43 SCC - Upper 4 cm 6 N0
2 M 78 SCC - Lower 3 cm 2 N0
3 F 53 ACC 9 Middle 2.5 cm 10 N0
4 F 61 Plasm 11 Middle 4 cm 2 N0
*Obstruction Score (Speiser, 199327): Tracheal obstruction > 50% = 10; < 50% = 6, and < 10% = 2.
DFS = disease free survival before first recurrence; Ext. = lesion extension; LN = lymph node involvement; M = male; F = female; SCC =
squamous cell carcinoma; ACC = adenoid cystic carcinoma; Plasm = plasmacytoma
Table 2 - Previous external beam radiation treatment (patient
# 1 did not receive external beam irradiation)
Patient Total dose Dose/fraction Tracheal location
2 50 Gy 2 Gy Lower
3 *60 Gy 2 Gy Middle
36 Gy 1.8 Gy Upper
4 **40 Gy 2 Gy Middle/lower
40 Gy Upper
*Two courses with 60 Gy and 36 Gy, respectively, in adjacent fields,
with a 6-month interval; ** Two courses of 40 Gy, in adjacent
fields, with a 5-year interval
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RESULTS
All patients presented complete local response at the
time of first bronchoscopic evaluation, with improvement
of related symptoms in 2 of the 3 symptomatic cases. No
biopsy was performed in order to avoid the risk of fistu-
lae or bleeding of the irradiated areas. The 2 patients with
squamous cell carcinoma died at 6th and 33rd months after
brachytherapy, respectively. The first, with no evidence of
local disease and persistent cough, died of respiratory in-
fection. No direct relationship with treatment was detected,
but in the last bronchoscopic evaluation, 3 months after
treatment, there was still moderate necrosis in the irradi-
ated areas, perhaps facilitating an infection. The second
patient, who received brachytherapy as a boost, died with
local recurrence 2 years after treatment. Two patients were
alive, with no evidence of disease at 64 and 110 months
of follow-up. Tracheal stenosis was observed in these 2
patients—and was considered a severe complication—22
and 69 months after brachytherapy, respectively. Both had
been extensively irradiated previously, with areas that re-
ceived 60 to 90 Gy (Table 4). A tracheal stent was suc-
cessfully placed for palliation in the patient with adenoid
cystic carcinoma, but it was not necessary for the plasma-
cytoma patient. During this period, this patient presented
other isolated lesions in the upper respiratory tract (lar-
ynx and oropharynx), and was successfully treated with
external beam irradiation. Nine years after brachytherapy,
she developed chronic lymphocytic leukemia.
No relationship of the brachytherapy irradiated volumes
and complications was observed.
DISCUSSION
Treatment of primary tracheal tumors has been optimized
over the years. At first, most patients were treated with endo-
scopic or surgical local excision followed by radiotherapy
with orthovoltage or radon seed implantation. One-year sur-
vival was less than 25%.15-17 Advances in surgical techniques
have made it possible to resect tracheal tumors that might
have previously been considered unresectable.18,19 At present,
surgery has become the primary treatment for tracheal
tumors.13,20 Advances in radiation therapy have shown mod-
est gains in the treatment of tracheal malignancies, either as
definitive or as adjuvant treatment.11,13,20-24
Schneider13 reported in his series of 14 resected cases, a
5-year survival of 35.7% for 6 patients who needed adjuvant
irradiation.
Kanematsu20 also reported, in 16 patients with adenoid
cystic carcinoma, a 5-and 10-year survival of 91% and 76%,
respectively, for patients with resected tumors versus a 5-year
Table 4 - Results and survival after the end of brachytherapy
Patient Survival DFS Cause of Local Sequelae
(months) (months) death recurrence
1 6 6 Respiratory No No
infection
2 33 24 Tumor Yes No
3 64 64 - No Stenosis
(22 months)
4 110 110 - No Stenosis
(69 months)
DFS = disease free survival
Table 3 - Brachytherapy characteristics
Patient Total dose BT total BT Interval between Number of V100 V150 V200 V150/V100 V200/V100
(whole EBR + BT)   dose dose/fraction fractions  catheters (cm3) (cm3) (cm3)
7.5 Gy 2 31.08 15.60 9.79 0.49 0.31
1 30 Gy 30 Gy 7.5 Gy 2 weeks 2 31.52 15.49 9.45 0.49 0.30
7.5 Gy 2 37.06 20.15 12.05 0.53 0.32
7.5 Gy 2 38.46 20.24 12.05 0.53 0.31
7.5 Gy 1 11.44 5.58 3.25 0.49 0.28
2 67.5 Gy 17.5 Gy 5.0 Gy 1 week 1 12.26 6.77 4.20 0.55 0.34
5.0 Gy 1 11.16 5.86 3.65 0.52 0.33
7.5 Gy 1 10.41 5.27 3.31 0.51 0.32
3 118.5 Gy 22.5 Gy 7.5 Gy 1 week 2 13.82 7.32 4.96 0.53 0.36
7.5 Gy 1 10.05 5.41 3.41 0.54 0.34
7.5 Gy 1 16.87 8.72 5.54 0.52 0.33
4 102.5 Gy 22.5 Gy 7.5 Gy 1 week 2 22.90 11.93 7.44 0.52 0.32
7.5 Gy 2 23.36 12.33 7.70 0.53 0.32
EBR: external beam radiotherapy; BT: brachytherapy; V100: volume enclosed by the 100% isodose curve; V150: volume enclosed by the
150% isodose curve; V200: volume enclosed by the 200% isodose curve
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survival of 40% when combined with radiation therapy.
Two Russian series25,26 of 48 patients with squamous cell
carcinoma of the trachea and 16 cases of adenoid cystic car-
cinoma had 5-year survival rates of 40.9% and 55.9%, re-
spectively, for patients treated with combined surgery and
radiotherapy.
Schraube et al.7 reported 5 patients treated with endo-
bronchial HDR brachytherapy: 4 combined with external
beam irradiation, and 1 as a salvage treatment after surgery.
External beam doses ranged from 46 to 60 Gy. Endobron-
chial HDR brachytherapy was delivered in 5 fractions of 3
to 4 Gy each, twice a week, calculated at 1 cm from the
source axis. They reported 4 of 5 complete responses, 2 of
3 deaths for recurrent or progressive disease, and 2 patients
alive with no evidence of disease at 37th and 68th months
of follow-up.
The same group published results some years later, with 7
cases treated with brachytherapy as a boost for residual tumor
after external irradiation. Local control was obtained in 5 of 7
patients, and late toxicity occurred in 3 patients (2 stenosis
and 1 hemorrhage). Three-year actuarial survival was 32%.3
In this series, all 4 patients achieved immediate complete
response, with palliation of symptoms and local control for at
least 6 months. Palliation was achieved mainly due to improve-
ment of obstruction. This might also have been evaluated by
pulmonary function tests, with determination of the maximum
flows, and thereby detecting impairment of high airways. But,
in the present study, these tests were not performed.
The patients with adenoid cystic carcinoma and plas-
macytoma had a better outcome, as expected. These patients
also presented with tracheal stenosis, and one of them was
treated with local stent placement. They persisted with only
mild limitations due to dyspnea. We considered the high
doses of either external beam irradiation, with a partial dose
overlap between fields, and endoluminal brachytherapy, to
have been the main cause of stenosis. It is conceivable that
more fractions with lower brachytherapy doses might have
avoided or diminished this risk.
Nevertheless, Schraube7 also reported 2 of 5 tracheitis
with stenosis in his series, and Harms3 reported 1 case of
late hemorrhage using 4 or 5 fractions of brachytherapy with
lower doses/fraction.
We observed that dose distribution using 2 catheters
seemed to be better than using a single one. The 100% isod-
ose curve may be widened to more than 2 cm diameter, al-
lowing better coverage of tracheal walls, which was associ-
ated with a lower surface dose (Table 3). This strategy may
be used to diminish the risk of complications, especially
when centralized catheters are not available.
CONCLUSIONS
Endobronchial HDR brachytherapy may be used for
tracheal tumors as a boost for external beam irradiation
or in recurrences. Total dose and dose/fraction have not
yet been well defined; however, 3 or 4 fractions of 5 to
7.5 Gy (at 1 cm depth) are currently used. Although sur-
vival impact was not demonstrated in this series, local
control of 3 out of 4 patients indicates that individual
cases may benefit from the treatment. Long-term survival
with palliation may also be expected mainly in cases of
adenoid cystic histology.
RESUMO
Carvalho H de A, Figueiredo V, Pedreira Jr. WL, Aisen S.
Braquiterapia de alta taxa de dose como opção terapêutica
nos tumores primários da traquéia. Clinics. 2005;60(4):299-
304.
OBJETIVO: Apresentar a experiência do tratamento de 4
pacientes com tumores primários de traquéia, não operados,
submetidos à braquiterapia endobrônquica de alta taxa de
dose.
PACIENTES E MÉTODOS: Dois casos de carcinoma
espinocelular, uma recidiva de carcinoma adenóide cístico
e uma recidiva de plasmocitoma primário da traquéia. Todos
receberam braquiterapia endobrônquica, exclusiva ou como
reforço de dose da radioterapia externa. Foram administradas
3 ou 4 frações de 7,5 Gy cada, calculados a 1 cm de
profundidade. O seguimento foi considerado a partir do
término da braquiterapia.
RESULTADOS: Em todos os casos houve resposta completa.
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